European Medicines Agency Publishes Concept Paper on Biomarker Best Practices


Last month the EMA published a “concept paper” to organize the drafting of a “Guideline on good genomics biomarker practices,” and to provide a way for interested parties to provide ideas and feedback on the proposal.

The proposed guidelines are being drafted to address a key problem in translational science, that being the ability to run clinical trials using the best information possible about suitable biomarkers.

The paper states: “The progress of technologies generates new knowledge in potential association of genomic biomarkers of health and disease at an unprecedented speed in science: however translation of this information into clinical tools currently lags behind.”

This is very much the problem that we are seeking to address with a comprehensive knowledge base like BiomarkerBase. The more we are able to include biomarkers in the database that have been well-validated, the more opportunity we provide to our users to identify the most effective biomarkers for their clinical trials and test products.


Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access